Alpha blockade potentiates CPVT therapy in calsequestrin-mutant mice

Area of Science:

• Cardiovascular Research
• Molecular Cardiology
• Arrhythmogenesis

Background:

• Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a life-threatening arrhythmia linked to spontaneous calcium release and delayed afterdepolarizations.
• While beta-blockers are first-line treatment, some CPVT patients require additional therapies like flecainide or surgical interventions.

Purpose of the Study:

• To investigate the potential of inhibiting the sympathetic nervous system via alpha-adrenergic blockade to optimize arrhythmia management in a mouse model of CPVT (CASQ2(Δ/Δ) mice).

Main Methods:

• Continuous electrocardiographic monitoring using implanted telemetry devices in CASQ2(Δ/Δ) mice.
• Analysis of calcium transients and release patterns in isolated cardiomyocytes.
• Assessment of adrenergic receptor expression via Western blotting and confocal microscopy.

Main Results:

• CASQ2(Δ/Δ) mice exhibited ventricular arrhythmias at rest and tachycardia during stress, which were not fully controlled by beta-blockers.
• Alpha-blocking agents (phentolamine, labetalol) abolished exercise- and epinephrine-induced arrhythmias.
• Alpha-adrenergic stimulation with phenylephrine provoked tachycardia, and alpha-blockade prevented stress-induced calcium release abnormalities in cardiomyocytes.

Conclusions:

• The alpha-adrenergic pathway plays a significant role in the development of catecholamine-induced arrhythmias in this CPVT model.
• Alpha-blockade represents a promising therapeutic strategy for CPVT patients unresponsive to beta-blockers.